The WUSTL-developed method detects a bile acid that is found at increased levels in Niemann-Pick patients, and is ready for pilot testing, its developers said.
At next week's workshop on the validation of LC/MS-based protein and peptide tests, the FDA hopes to determine what it needs to demand from test developers.
Agilent will provide technology and training for the jointly-run lab, expanding on a 2011 deal to open a microarray technology center at Monash University Malaysia.
Scientists from the Okinawa Institute of Science and Technology and Kyoto University have found 14 metabolites whose levels differ in older individuals' blood.
The announcement comes as the agency is preparing to regulate laboratory developed tests as medical devices, including those based on mass spectrometry.
Yale Environment 360 writes that synthetic and conservation biologists aren't always on the same wavelength, but they are trying to reach an understanding.
